title: A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome.
abstract: OBJECTIVE
  The aim of this study was to ascertain whether high-dose intravenous (IV) iron sucrose could improve symptoms and change brain iron concentrations in idiopathic RLS.
  
  
  METHODS
  The study was a randomized, parallel-group double-blind study of 1000mg iron sucrose given IV versus placebo. Primary measures of the clinical status were global rating scale (GRS) and periodic leg movements of sleep (PLMS). Primary measures of brain iron status were CSF ferritin and MRI-determined iron in the substantia nigra.
  
  
  RESULTS
  At the time of the interim analysis there were 7 placebo and 11 iron-treated subjects. At 2-weeks post-treatment, iron treatment resulted in a small but significant increase in CSF ferritin and a decrease in RLS severity (GRS) but did not change PLMS or MRI iron index. None of the secondary outcomes changed with treatment. There was no single case of clear treatment benefit in any of the patients. This interim analysis revealed an effect size that was too small to allow for adequate power to find significant differences with the planed 36-subject enrollment for either the primary objective outcome of PLMS or any of the secondary outcomes. The study was stopped at this planned break-point given the lack of both adequate power and any indication for clinically significant benefit.
  
  
  CONCLUSIONS
  High-dose IV iron failed to demonstrate the robust changes reported in three prior open-label studies. Differences in iron formulation, dosing regiment, and peripheral iron status may explain some of the discrepancies between this and previous IV iron treatment studies.
authors.affiliation: Department of Neurology, Johns Hopkins University, Johns Hopkins Bayview Medical Center, 5501 Hopkins Bayview Circle, AAC 1B-82, Baltimore, MD 21224, USA. cearley@jhmi.edu
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Earley
authors.forename: Alena
authors.initials: A
authors.lastname: Horská
authors.forename: Mona A
authors.initials: MA
authors.lastname: Mohamed
authors.forename: Peter B
authors.initials: PB
authors.lastname: Barker
authors.forename: John L
authors.initials: JL
authors.lastname: Beard
authors.forename: Richard P
authors.initials: RP
authors.lastname: Allen
mesh_terms: D000368:Aged; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005290:Ferric Compounds / Q000627:therapeutic use*; D000077605:Ferric Oxide, Saccharated; D005293:Ferritins / Q000134:cerebrospinal fluid; D005937:Glucaric Acid; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D007501:Iron / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012148:Restless Legs Syndrome / Q000188:drug therapy* / Q000378:metabolism; D013378:Substantia Nigra / Q000378:metabolism; D017211:Treatment Failure
chemical_list: D005290:Ferric Compounds; D006397:Hematinics; D005293:Ferritins; D007501:Iron; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid